ketanserin has been researched along with Liver Diseases in 2 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketanserin is a serotonin S2-receptor antagonist introduced for the treatment of arterial hypertension and vasospastic disorders." | 2.38 | Clinical pharmacokinetics of ketanserin. ( Hedner, T; Heykants, J; Persson, B, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Persson, B | 1 |
| Heykants, J | 1 |
| Hedner, T | 1 |
| Weiss, M | 1 |
1 review available for ketanserin and Liver Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of ketanserin.
Topics: Aging; Drug Interactions; Humans; Ketanserin; Kidney Diseases; Liver Diseases | 1991 |
1 other study available for ketanserin and Liver Diseases
| Article | Year |
|---|---|
Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.
Topics: Absorption; Antipyrine; Biological Availability; Caffeine; Diphenhydramine; Dose-Response Relationsh | 1990 |